Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

Coya sees IL-2 as a molecule that can boost the number and power of regulatory T cells (Tregs), leading it to study it as a single agent, COYA 301, and pair the cytokine with the recombinant ...

Imugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analysts ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

MDNA11 is a next-generation IL-2 superkine designed to selectively stimulate effector immune cells (CD8 + T cells and NK cells) by enhancing affinity for IL-2Rβ (CD122) while avoiding IL-2Rα (CD25), ...

Discover a study that shows that modulating STAT6 directly may represent an innovative strategy for managing severe, ...

In vitro experiments revealed that lack of IL-2 production by CD4+ T cells accounts for the loss of CD25 expression in SLE Treg, which could be selectively reversed by stimulation with low doses of IL ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of ...